Which is first? The controversial issue of precedence in the treatment of male sexual dysfunctions

Journal of Sexual Medicine

Volumn 10, Issue 10, 2013, Pages 2359-2369

  Jannini, Emmanuele A ^a   Isidori, Andrea M ^b   Aversa, Antonio ^b   Lenzi, Andrea ^b   Althof, Stanley E ^c  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dapoxetine; Flowchart; Precedence; Sildenafil; Tadalafil; Testosterone; Vardenafil

Indexed keywords

CITALOPRAM; DAPOXETINE; FLUOXETINE; PAROXETINE; PHOSPHODIESTERASE V INHIBITOR; SERTRALINE; TESTOSTERONE; UNDECANOIC ACID;

ANDROGEN THERAPY; ARTICLE; CARDIOVASCULAR MORTALITY; COMORBIDITY; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DISTRESS SYNDROME; DIZZINESS; DOPAMINERGIC NERVE CELL; DRUG INDUCED HEADACHE; DYSLIPIDEMIA; EJACULATION; ERECTILE DYSFUNCTION; FATIGUE; HEMATOCRIT; HUMAN; HYPOGONADISM; INSOMNIA; LATENT PERIOD; LIBIDO DISORDER; LIFESTYLE MODIFICATION; LUBRICATION; MEDICAL HISTORY; NAUSEA; OBESITY; OSTEOPOROSIS; PATIENT COUNSELING; PERFORMANCE ANXIETY; PHARMACEUTICAL CARE; PHYSICAL EXAMINATION; PREMATURE EJACULATION; PRIORITY JOURNAL; PROSTATITIS; PSYCHOLOGICAL ASPECT; PSYCHOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; RISK; SKIN IRRITATION; SOMNOLENCE; TESTOSTERONE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

DAPOXETINE; FLOWCHART; PRECEDENCE; SILDENAFIL; TADALAFIL; TESTOSTERONE; VARDENAFIL;

ADULT; BENZYLAMINES; COMORBIDITY; COUNSELING; CRITICAL PATHWAYS; DRUG THERAPY, COMBINATION; EJACULATION; ERECTILE DYSFUNCTION; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; NAPHTHALENES; PATIENT SELECTION; PENILE ERECTION; PHOSPHODIESTERASE 5 INHIBITORS; PREMATURE EJACULATION; SEROTONIN UPTAKE INHIBITORS; SEXUAL BEHAVIOR; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84885895415     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12315     Document Type: Article

References (68)

1. McNutt WF. Vis medicatrix naturae. Calif State J Med 1923;21:510-511.
2. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O'Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363:123-135.
3. Wang C, Nieschlag E, Swerdloff RS, Behre H, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC. ISA, ISSAM, EAU, EAA and ASA recommendations: Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2009;12:5-12.
4. Qaseem A, Snow V, Denberg TD, Casey DE Jr, Forciea MA, Owens DK, Shekelle P. Hormonal testing and pharmacologic treatment of erectile dysfunction: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2009;151:639-649.
5. Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M, Orlando C, Vannelli GB, Aversa A, Natali A, Forti G, Giorgi M, Jannini EA, Ledda F, Maggi M. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 2004;145:2253-2263.
6. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2008;179:S97-102.
7. Buvat J, Montorsi F, Maggi M, Porst H, Kaipia A, Colson MH, Cuzin B, Moncada I, Martin-Morales A, Yassin A, Meuleman E, Eardley I, Dean JD, Shabsigh R. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med 2011;8:284-293.
8. Giltay EJ, Tishova YA, Mskhalaya GJ, Gooren LJ, Saad F, Kalinchenko SY. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med 2010;7:2572-2582.
9. Zitzmann M. Pharmacogenetics of testosterone replacement therapy. Pharmacogenomics 2009;10:1341-1349.
10. Jannini EA, Isidori AM, Gravina GL, Aversa A, Balercia G, Bocchio M, Boscaro M, Carani C, Corona G, Fabbri A, Foresta C, Forti G, Francavilla S, Granata AR, Maggi M, Mansani R, Palego P, Spera G, Vetri M, Lenzi A. The ENDOTRIAL study: A spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction. J Sex Med 2009;6:2547-2560.
11. Debruyne FM, Gittelman M, Sperling H, Borner M, Beneke M. Time to onset of action of vardenafil: A retrospective analysis of the pivotal trials for the orodispersible and film-coated tablet formulations. J Sex Med 2011;8:2912-2923.
12. Warde N. Therapy: Two birds, one stone: Tadalafil is an effective treatment for men with both BPH-LUTS and ED. Nat Rev Urol 2011;8:643.
13. D'Amati G, di Gioia CR, Bologna M, Giordano D, Giorgi M, Dolci S, Jannini EA. Type 5 phosphodiesterase expression in the human vagina. Urology 2002;60:191-195.
14. Mancina R, Filippi S, Marini M, Morelli A, Vignozzi L, Salonia A, Montorsi F, Mondaini N, Vannelli GB, Donati S, Lotti F, Forti G, Maggi M. Expression and functional activity of phosphodiesterase type 5 in human and rabbit vas deferens. Mol Hum Reprod 2005;11:107-115.
15. Rubio-Casillas A, Jannini EA. New insights from one case of female ejaculation. J Sex Med 2011;8:3500-3504.
16. Corona G, Petrone L, Mannucci E, Jannini EA, Mansani R, Magini A, Giommi R, Forti G, Maggi M. Psycho-biological correlates of rapid ejaculation in patients attending an andrologic unit for sexual dysfunctions. Eur Urol 2004;46:615-622.
17. Althof SE, Abdo CH, Dean J, Hackett G, McCabe M, McMahon CG, Rosen RC, Sadovsky R, Waldinger M, Becher E, Broderick GA, Buvat J, Goldstein I, El-Meliegy AI, Giuliano F, Hellstrom WJ, Incrocci L, Jannini EA, Park K, Parish S, Porst H, Rowland D, Segraves R, Sharlip I, Simonelli C, Tan HM. International Society for Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation. J Sex Med 2010;7:2947-2969.
18. Aversa A, Francomano D, Bruzziches R, Natali M, Spera G, Lenzi A. Is there a role for phosphodiesterase type-5 inhibitors in the treatment of premature ejaculation? Int J Impot Res 2011;23:17-23.
19. Jannini EA, Lenzi A, Wagner G. New perspectives in the pharmacotherapy of erectile dysfunction. IDrugs 2003;6:1165-1172.
20. Jannini EA, Lenzi A, Isidori A, Fabbri A. Subclinical erectile dysfunction: Proposal for a novel taxonomic category in sexual medicine. J Sex Med 2006;3:787-793.
21. McMahon CG, McMahon CN, Leow LJ, Winestock CG. Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: A systematic review. BJU Int 2006;98:259-272.
22. Jannini EA, McCabe MP, Salonia A, Montorsi F, Sachs BD. Organic vs. psychogenic? The Manichean diagnosis in sexual medicine. J Sex Med 2010;7:1726-1733.
23. Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, Isidori A, Fabbri A, Lenzi A. Effects of testosterone on sexual function in men: Results of a meta-analysis. Clin Endocrinol 2005;63:381-394.
24. Bolona ER, Uraga MV, Haddad RM, Tracz MJ, Sideras K, Kennedy CC, Caples SM, Erwin PJ, Montori VM. Testosterone use in men with sexual dysfunction: A systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007;82:20-28.
25. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, Swerdloff RS. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004;89:2085-2098.
26. Zitzmann M, Mattern A, Hanisch J, Gooren L, Jones H, Maggi M. IPASS: A study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1, 438 men. J Sex Med 2013;10:579-588.
27. Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 2011;165:675-685.
28. Schneider G, Nienhaus K, Gromoll J, Heuft G, Nieschlag E, Zitzmann M. Depressive symptoms in men aged 50 years and older and their relationship to genetic androgen receptor polymorphism and sex hormone levels in three different samples. Am J Geriatr Psychiatry 2011;19:274-283.
29. Giannetta E, Gianfrilli D, Barbagallo F, Isidori AM, Lenzi A. Subclinical male hypogonadism. Best Pract Res Clin Endocrinol Metab 2012;26:539-550.
30. Jannini EA, Screponi E, Carosa E, Pepe M, Lo Giudice F, Trimarchi F, Benvenga S. Lack of sexual activity from erectile dysfunction is associated with a reversible reduction in serum testosterone. Int J Androl 1999;22:385-392.
31. Carosa E, Benvenga S, Trimarchi F, Lenzi A, Pepe M, Simonelli C, Jannini EA. Sexual inactivity results in reversible reduction of LH bioavailability. Int J Impot Res 2002;14:93-99; discussion 100.
32. Carosa E, Martini P, Brandetti F, Di Stasi SM, Lombardo F, Lenzi A, Jannini EA. Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levels. Clin Endocrinol (Oxf) 2004;61:382-386.
33. Balercia G, Boscaro M, Lombardo F, Carosa E, Lenzi A, Jannini EA. Sexual symptoms in endocrine diseases: Psychosomatic perspectives. Psychother Psychosom 2007;76:134-140.
34. Spitzer M, Basaria S, Travison TG, Davda MN, Paley A, Cohen B, Mazer NA, Knapp PE, Hanka S, Lakshman KM, Ulloor J, Zhang A, Orwoll K, Eder R, Collins L, Mohammed N, Rosen RC, DeRogatis L, Bhasin S. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: A parallel, randomized trial. Ann Intern Med 2012;157:681-691.
35. Isidori AM, Lenzi A. Risk factors for androgen decline in older males: Lifestyle, chronic diseases and drugs. J Endocrinol Invest 2005;28:14-22.
36. Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A, Forti G, Mannucci E, Maggi M. Hypogonadism as a risk factor for cardiovascular mortality in men: A meta-analytic study. Eur J Endocrinol 2011;165:687-701.
37. Aversa A, Bruzziches R, Francomano D, Rosano G, Isidori AM, Lenzi A, Spera G. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: Results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 2010;7:3495-3503.
38. Pepe J, Isidori AM, Falciano M, Iaiani G, Salotti A, Diacinti D, Del Fiacco R, Sbardella E, Cipriani C, Piemonte S, Romagnoli E, Lenzi A, Minisola S. The combination of FRAX and Ageing Male Symptoms scale better identifies treated HIV males at risk for major fracture. Clin Endocrinol 2012;77:672-678.
39. Corona G, Jannini EA, Mannucci E, Fisher AD, Lotti F, Petrone L, Balercia G, Bandini E, Chiarini V, Forti G, Maggi M. Different testosterone levels are associated with ejaculatory dysfunction. J Sex Med 2008;5:1991-1998.
40. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl 2009;30:1-9.
41. Shamloul R, Ghanem H, Fahmy I, El-Meleigy A, Ashoor S, Elnashaar A, Kamel I. Testosterone therapy can enhance erectile function response to sildenafil in patients with PADAM: A pilot study. J Sex Med 2005;2:559-564.
42. Aversa A, Jannini EA, Maggi M, Lenzi A. Effects of testosterone replacement on response to sildenafil citrate. Ann Intern Med 2013;158:569-570.
43. Fabbri A, Giannetta E, Lenzi A, Isidori AM. Testosterone treatment to mimic hormone physiology in androgen replacement therapy. A view on testosterone gel and other preparations available. Expert Opin Biol Ther 2007;7:1093-1106.
44. McMahon CG, Althof SE, Waldinger MD, Porst H, Dean J, Sharlip ID, Adaikan PG, Becher E, Broderick GA, Buvat J, Dabees K, Giraldi A, Giuliano F, Hellstrom WJ, Incrocci L, Laan E, Meuleman E, Perelman MA, Rosen RC, Rowland DL, Segraves R. An evidence-based definition of lifelong premature ejaculation: Report of the International Society for Sexual Medicine (ISSM) ad hoc committee for the definition of premature ejaculation. J Sex Med 2008;5:1590-1606.
45. Carani C, Isidori AM, Granata A, Carosa E, Maggi M, Lenzi A, Jannini EA. Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients. J Clin Endocrinol Metab 2005;90:6472-6479.
46. Corona G, Jannini EA, Vignozzi L, Rastrelli G, Maggi M. The hormonal control of ejaculation. Nat Rev Urol 2012;9:508-519.
47. Hull EM, Du J, Lorrain DS, Matuszewich L. Extracellular dopamine in the medial preoptic area: Implications for sexual motivation and hormonal control of copulation. J Neurosci 1995;15:7465-7471.
48. Wang WF, Chang L, Minhas S, Ralph DJ. Selective serotonin reuptake inhibitors in the treatment of premature ejaculation. Chin Med J 2007;120:1000-1006.
49. Abdel-Hamid IA, Jannini EA, Andersson KE. Premature ejaculation: Focus on therapeutic targets. Expert Opin Ther Targets 2009;13:175-193.
50. McMahon CG, Althof SE, Kaufman JM, Buvat J, Levine SB, Aquilina JW, Tesfaye F, Rothman M, Rivas DA, Porst H. Efficacy and safety of dapoxetine for the treatment of premature ejaculation: Integrated analysis of results from five phase 3 trials. J Sex Med 2011;8:524-539.
51. Jannini EA, Maggi M, Lenzi A. Evaluation of premature ejaculation. J Sex Med 2011;8(4 suppl):328-334.
52. Jannini EA, Lombardo F, Lenzi A. Correlation between ejaculatory and erectile dysfunction. Int J Androl 2005;28:S40-45.
53. Asimakopoulos AD, Miano R, Finazzi Agro E, Vespasiani G, Spera E. Does current scientific and clinical evidence support the use of phosphodiesterase type 5 inhibitors for the treatment of premature ejaculation? A systematic review and meta-analysis. J Sex Med 2012;9:2404-2416.
54. Jern P, Eriksson E, Westberg L. A reassessment of the possible effects of the serotonin transporter gene linked polymorphism 5-HTTLPR on premature ejaculation. Arch Sex Behav 2013;42:45-49.
55. Aversa A, Pili M, Francomano D, Bruzziches R, Spera E, La Pera G, Spera G. Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation. Int J Impot Res 2009;21:221-227.
56. Francomano D, Donini L, Lenzi A, Aversa A. Peripheral arterial tonometry to measure the effects of vardenafil on sympathetic tone in men with lifelong premature ejaculation. Int J Endocrinol 2013;2013:394934.
57. Jannini EA, Simonelli C, Lenzi A. Sexological approach to ejaculatory dysfunction. Int J Androl 2002;25:317-323.
58. Jannini EA, Lenzi A. Introduction to the integrated model: Medical, surgical and psychological therapies for the couple. J Endocrinol Invest 2003;26:128-131.
59. McCarthy BW, Fucito LM. Integrating medication, realistic expectations, and therapeutic interventions in the treatment of male sexual dysfunction. J Sex Marital Ther 2005;31:319-328.
60. Althof S, McCabe M, Assalian P, Chevret-Measson M, Lieblum S, Simonelli C, Wylie K. Psychosocial and interpersonal dimensions of sexual function and dysfunction. In: Montorsi F, Basson R, Adaikan G, Becher E, Clayton A, Guiliano F, Khoury S, Sharlip I, eds. Sexual medicine: Sexual dysfunction in men and women. Paris: Editions 21; 2010:121-181.
61. Althof S. When an erection alone is not enough; biopsychosocial obstacles to lovemaking. Int J Impot Res 2002;14:S99-104.
62. Althof S. Sex therapy in the age of pharmacotherapy. Ann Rev Sex Res 2006;17:116-132.
63. Perelman MA. A new combination treatment for premature ejaculation: A sex therapist's perspective. J Sex Med 2006;3:1004-1012.
64. Abdo CH, Afif-Abdo J, Otani F, Machado AC. Sexual satisfaction among patients with erectile dysfunction treated with counseling, sildenafil, or both. J Sex Med 2008;5:1720-1726.
65. Aubin S, Heiman JR, Berger RE, Murallo AV, Yung-Wen L. Comparing Sildenafil alone vs. Sildenafil plus brief couple sex therapy on erectile dysfunction and couples' sexual and marital quality of life: A pilot study. J Sex Marital Ther 2009;35:122-143.
66. Melnik T, Soares BG, Nasello AG. The effectiveness of psychological interventions for the treatment of erectile dysfunction: Systematic review and meta-analysis, including comparisons to sildenafil treatment, intracavernosal injection, and vacuum devices. J Sex Med 2008;5:2562-2574.
67. Conaglen HM, Conaglen JV. Couples' reasons for adherence to, or discontinuation of, PDE type 5 inhibitors for men with erectile dysfunction at 12 to 24-month follow-up after a 6-month free trial. J Sex Med 2012;9:857-865.
68. Goldstein I, Mulhall JP, Bushmakin AG, Cappelleri JC, Hvidsten K, Symonds T. The erection hardness score and its relationship to successful sexual intercourse. J Sex Med 2008;5:2374-2380.